Ubs Group Ag Dynavax Technologies Corp Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Ubs Group Ag holds 243,373 shares of DVAX stock, worth $3.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

243,373

Previous 195,269 24.63%

Holding current value

$3.1 Million

Previous $2.19 Million 23.68%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $11.61 $483,445 - $558,487	48,104 Added 24.63%	243,373 $2.71 Million
Q2 2024 Aug 13, 2024	SELL	$10.73 - $12.58 $2.66 Million - $3.11 Million	-247,557 Reduced 55.9%	195,269 $2.19 Million
Q1 2024 May 13, 2024	SELL	$11.7 - $14.98 $2.4 Million - $3.07 Million	-205,085 Reduced 31.65%	442,826 $5.5 Million
Q4 2023 Feb 09, 2024	BUY	$13.09 - $14.98 $6.87 Million - $7.86 Million	525,012 Added 427.19%	647,911 $9.06 Million
Q3 2023 Nov 09, 2023	SELL	$12.64 - $14.99 $2.3 Million - $2.73 Million	-181,862 Reduced 59.67%	122,899 $1.82 Million
Q2 2023 Aug 11, 2023	BUY	$9.85 - $13.17 $802,233 - $1.07 Million	81,445 Added 36.47%	304,761 $3.94 Million
Q1 2023 May 12, 2023	SELL	$9.44 - $11.88 $1.95 Million - $2.46 Million	-207,009 Reduced 48.11%	223,316 $2.19 Million
Q4 2022 Feb 08, 2023	BUY	$10.27 - $13.29 $3.19 Million - $4.13 Million	311,084 Added 260.89%	430,325 $4.58 Million
Q3 2022 Nov 10, 2022	BUY	$9.93 - $17.44 $120,073 - $210,884	12,092 Added 11.29%	119,241 $1.25 Million
Q2 2022 Aug 10, 2022	SELL	$7.45 - $12.83 $1.38 Million - $2.38 Million	-185,866 Reduced 63.43%	107,149 $1.35 Million
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $2.56 Million - $3.79 Million	262,650 Added 864.98%	293,015 $3.18 Million
Q4 2021 Feb 14, 2022	BUY	$13.17 - $20.94 $69,959 - $111,233	5,312 Added 21.2%	30,365 $427,000
Q3 2021 Nov 15, 2021	SELL	$9.16 - $19.83 $217,476 - $470,803	-23,742 Reduced 48.66%	25,053 $481,000
Q2 2021 Aug 13, 2021	SELL	$7.25 - $10.99 $1.02 Million - $1.54 Million	-140,223 Reduced 74.18%	48,795 $481,000
Q1 2021 May 12, 2021	BUY	$4.57 - $11.18 $764,839 - $1.87 Million	167,361 Added 772.78%	189,018 $1.86 Million
Q4 2020 Feb 11, 2021	SELL	$3.73 - $5.6 $9,526 - $14,302	-2,554 Reduced 10.55%	21,657 $96,000
Q3 2020 Nov 12, 2020	BUY	$4.32 - $11.7 $63,188 - $171,135	14,627 Added 152.62%	24,211 $105,000
Q2 2020 Jul 31, 2020	SELL	$2.94 - $9.1 $91,633 - $283,628	-31,168 Reduced 76.48%	9,584 $85,000
Q1 2020 May 01, 2020	SELL	$2.27 - $6.2 $87,646 - $239,388	-38,611 Reduced 48.65%	40,752 $144,000
Q4 2019 Feb 14, 2020	BUY	$3.46 - $6.93 $37,143 - $74,393	10,735 Added 15.64%	79,363 $454,000
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $129,792 - $234,012	48,250 Added 236.77%	68,628 $245,000
Q2 2019 Aug 14, 2019	SELL	$3.65 - $7.89 $95,659 - $206,781	-26,208 Reduced 56.26%	20,378 $82,000
Q1 2019 May 14, 2019	SELL	$7.08 - $12.09 $270,321 - $461,608	-38,181 Reduced 45.04%	46,586 $341,000
Q4 2018 Feb 14, 2019	BUY	$8.14 - $13.28 $198,835 - $324,390	24,427 Added 40.48%	84,767 $776,000
Q3 2018 Nov 14, 2018	BUY	$11.85 - $16.0 $566,821 - $765,328	47,833 Added 382.45%	60,340 $748,000
Q2 2018 Aug 14, 2018	SELL	$15.15 - $20.75 $3.67 Million - $5.03 Million	-242,180 Reduced 95.09%	12,507 $191,000
Q1 2018 May 15, 2018	BUY	$14.65 - $19.9 $2.38 Million - $3.23 Million	162,360 Added 175.85%	254,687 $5.06 Million
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $312,818 - $435,414	-18,082 Reduced 16.38%	92,327 $1.73 Million
Q3 2017 Nov 14, 2017	BUY	$15.2 - $21.5 $1.11 Million - $1.57 Million	73,029 Added 195.37%	110,409 $2.37 Million
Q2 2017 Aug 14, 2017	BUY	N/A	34,088 Added 1035.48%	37,380 $361,000
Q1 2017 Nov 14, 2017	BUY	N/A	3,292	3,292 $20,000

Others Institutions Holding DVAX

# of Institutions

275

Shares Held

130M

Call Options Held

451K

Put Options Held

203K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account